CYP2A6 gene polymorphism and risk of liver cancer and cirrhosis

Pharmacogenetics

Volumn 7, Issue 3, 1997, Pages 247-250

  Gullstén, Harriet ^a   Agúndez, Jose A G ^b   Benítez, Julio ^b   Läärä, Esa ^a   Ladero, José María ^c   Díaz Rubio, Manuel ^c   Fernandez Salguero, Pedro ^d   Gonzalez, Frank ^d   Rautio, Arja ^a   Pelkonen, Olavi ^a   Raunio, Hannu ^a  

^a UNIVERSITY OF OULU   (Finland)

^b UNIVERSITY OF EXTREMADURA   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cirrhosis; CYP2A6 gene polymorphism; Liver cancer

Indexed keywords

CYTOCHROME P450 ISOENZYME;

ADULT; AGED; ARTICLE; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; CARCINOMA, HEPATOCELLULAR; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; RISK FACTORS; SPAIN;

EID: 8544278026     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199706000-00010     Document Type: Article

References (18)

1. Agúndez JAG, Ledesma MC, Benitez J, Ladero JM, Rodriguez-Lescure A, Diaz-Rubio E, Diaz-Rubio M. CYP2D6 genes and risk of liver cancer. Lancet 1995: 345, 830-831.
2. 1. Proc Natl Acad Sci USA 1990: 87, 4790-4793.
3. Camus A-M, Geneste O, Honkakoski P, Bereziat J-C, Henderson CJ, Wolf CR, Bartsch H, Lang MA. High variability of nitrosamine metabolism among individuals: role of cytochromes P450 2A6 and 2E1 in the dealkylation of N-nitrosodimethylamine and N-nitrosodiethylamine in mice and humans. Mol Carcinog 1993: 7, 268-275.
4. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang J-D, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR, Zanger UM. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996b: 6, 193-201.
5. Ding S, Lake BG, Friedberg T, Wolf CR. Expression and alternative splicing of the cytochrome P-450 CYP2A7. Biochem J 1995: 306, 161-166.
6. Duescher RJ, Elfarra AA. Human liver microsomes are efficient catalysts of 1,3-butadiene oxidation: evidence for major roles by cytochromes P450 2A6 and 2E1. Arch Biochem Biophys 1994: 311, 342-349.
7. Fernandez-Salguero P, Gonzalez FJ. The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. Pharmacogenetics 1995: 5, S123-S128.
8. Fernandez-Salguero P, Hoffman SMG, Cholerton S, Mohrenweiser H, Raunio H, Rautio A, Pelkonen O, Huang J, Evans WE, Idle JR, Gonzalez FJ. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet 1995: 57, 651-660.
9. Hoffman SMG, Fernandez-Salguero P, Gonzalez FJ, Mohrenweiser HW. Organization and evolution of the cytochrome P4500 CYP2A-2B-2F subfamily gene cluster on human chromosome 19. J Molec Evolut 1995: 41, 894-900.
10. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 56. Some Naturally Occurring Sustances: Food Items and Constituents, Heterocyclic Aromatic Amines and Mycotoxins. Lyon, France: IARC; 1993.
11. Mehta C, Patel N. Statistical Software for Exact Nonparametric Inference. User Manual. Cambridge: Cytel Software Corporation; 1995.
12. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996: 6, 1-42.
13. Pelkonen O, Raunio H, Rautio A, Mäenpää J, Lang MA. Coumarin 7-hydroxylase: characteristics and regulation in mouse and man. J Irish Coll Phys Surg 1993: 22, 24-28.
14. Salonpää P, Hakkola J, Pasanen M, Pelkonen O, Vähäkangas K, Battula N, Nouso K, Raunio H. Retrovirus-mediated stable expression of human CYP2A6 in mammalian cells. Eur J Pharmacol Environ Toxicol Pharmacol 1993: 248, 95-102.
15. Tiano HF, Wang R-L, Hosokawa M, Crespi C, Tindall KR, Langenbach R. Human CYP2A6 activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK): mutational specificity in the gpt gene of AS52 cells. Carcinogenesis 1994: 15, 2859-2866.
16. Yamano S, Tatsuno J, Gonzalez FJ. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 1990: 29, 1322-1329.
17. Yamazki H, Inui Y, Yun C-H, Guengerich FP, Shimada T. Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 1992: 13, 1789-1794.
18. Yun C-H, Shimada T, Guengerich FP. Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol Pharmacol 1991: 40, 679-685.